David Saxon, an analyst from Needham, reiterated the Buy rating on Cooper Co. The associated price target remains the same with $94.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
David Saxon has given his Buy rating due to a combination of factors influencing Cooper Co’s performance. Despite the recent quarter’s revenue aligning with expectations and an earnings per share surpassing forecasts, there were challenges such as a shift in customer preference from clariti to MyDay and pressure in the APAC E-commerce channel for CVI. However, management anticipates that if trial volumes for MyDay convert into orders, it could counterbalance the decline in clariti sales.
Additionally, while the fertility segment within CSI faced delays in capital purchases, there are signs of improvement. Looking ahead to fiscal year 2026, management projects growth acceleration, with CVI expected to match or exceed the contact lens market growth and CSI gaining market share. Despite the disappointment from the guidance revision, the stock’s valuation at approximately 15 times the CY26 EPS in after-hours trading presents a favorable risk/reward scenario, supporting the Buy recommendation.
In another report released on August 19, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $84.00 price target.